BioSpace News Archive

Relmada Therapeutics, Inc. today announced top-line results of the human abuse potential (HAP) study with REL-1017, a novel NMDA receptor (NMDAR) channel blocker and the company’s lead candidate in Phase 3 development for the treatment major depressive disorder (MDD).

LivaNova PLC, a market-leading medical technology and innovation company, reported results for the quarter and full year ended December 31, 2021.

NovaBay ® Pharmaceuticals, Inc . announces the engagement of one of China’s leading marketing firms for omnichannel integrated marketing and branding services of DERMAdoctor skincare products in China.

Leadership to Outline Merck’s Vision to Drive Long-Term Business Value through ESG.

Amryt today announces that its unaudited financial results for the fourth quarter 2021 and full year ended December 31, 2021 will be released on Wednesday, March 9, 2022 at 0700 EST / 1200 GMT.

Mirion Technologies, Inc. today announced results for its fiscal quarter and fiscal year ended December 31, 2021.

Aadi Bioscience, Inc. today announced the launch and commercial availability of its first proprietary product, FYARRO™ (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for intravenous use for the treatment of adult patients with locally advanced unresectable or metastatic malignant PEComa.

BioTheryX, Inc. today announced that Nancy Miller-Rich has assumed the role of Chair of the BioTheryX Board of Directors.

Mednow completed the acquisitions of London Pharmacare Inc. and Liver Care Canada Inc.

Averix Bio today announces its submission of a Drug Master File (DMF) to the US Food & Drug Administration (FDA) for cannabidiol (CBD) isolate.